Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × canakinumab × Dermatologic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 9 Gastrointestinal 3 Myeloid 2 Other hematologic neoplasm 1 Genitourinary 1 Dermatologic 1 Classical hematology 1 Breast 1

Conditions

Interventions

pembrolizumab 283 Nivolumab 249 Ipilimumab 223 Cyclophosphamide 172 aldesleukin 129 Interleukin-2 94 fludarabine phosphate 92 fludarabine 74 trametinib 68 Radiotherapy 68 Dacarbazine 68 Temozolomide 66 dabrafenib 60 Vemurafenib 60 Biopsy 55 Radiosurgery 48 Bevacizumab 46 sargramostim 43 Magnetic Resonance Spectroscopy 43 Imiquimod 43 Aminolevulinic Acid 42 Peripheral Blood Stem Cell Transplantation 40 Paclitaxel 40 Cisplatin 40 Carboplatin 39 3-ingenyl angelate 38 Specimen Handling 36 incomplete Freund's adjuvant 35 binimetinib 35 Melphalan 35

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03484923 2024-06-18

PLATforM

Novartis

Phase 2 Completed

196 enrolled 22 charts

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡